129 related articles for article (PubMed ID: 15929187)
1. Pivotal molecules of MHC I pathway in human primary hepatocellular carcinoma.
Chen W; Cai MY; Wei DP; Wang X
World J Gastroenterol; 2005 Jun; 11(21):3297-9. PubMed ID: 15929187
[TBL] [Abstract][Full Text] [Related]
2. HLA class I expression in primary hepatocellular carcinoma.
Huang J; Cai MY; Wei DP
World J Gastroenterol; 2002 Aug; 8(4):654-7. PubMed ID: 12174373
[TBL] [Abstract][Full Text] [Related]
3. Expression of class I MHC molecule, HSP70 and TAP in human hepatocellular carcinoma.
Deng XL; Chen W; Cai MY; Wei DP
World J Gastroenterol; 2003 Aug; 9(8):1853-5. PubMed ID: 12918137
[TBL] [Abstract][Full Text] [Related]
4. Higher human lymphocyte antigen class I expression in early-stage cancer cells leads to high sensitivity for cytotoxic T lymphocytes.
Akazawa Y; Nobuoka D; Takahashi M; Yoshikawa T; Shimomura M; Mizuno S; Fujiwara T; Nakamoto Y; Nakatsura T
Cancer Sci; 2019 Jun; 110(6):1842-1852. PubMed ID: 30973665
[TBL] [Abstract][Full Text] [Related]
5. Concordant expression of proto-oncogene promyelocytic leukemia and major histocompatibility antigen HLA class I in human hepatocellular carcinoma.
Xia M; Zhang JQ; Shen YQ; Xu LH; Chen AQ; Miao FQ; Xie W
Tissue Antigens; 2007 Oct; 70(4):272-82. PubMed ID: 17767548
[TBL] [Abstract][Full Text] [Related]
6. Increased frequencies of CD8+ T lymphocytes recognizing wild-type p53-derived epitopes in peripheral blood correlate with presence of epitope loss tumor variants in patients with hepatocellular carcinoma.
Cicinnati VR; Zhang X; Yu Z; Ferencik S; Schmitz KJ; Dworacki G; Kaczmarek E; Oldhafer K; Frilling A; Baba HA; Schmid KW; Grosse-Wilde H; Broelsch CE; DeLeo AB; Gerken G; Beckebaum S
Int J Cancer; 2006 Dec; 119(12):2851-60. PubMed ID: 16998881
[TBL] [Abstract][Full Text] [Related]
7. Class I and class II major histocompatibility complex antigens expression on human hepatocytes and hepatoma cells: an approach with high sensitivity and specificity.
Chiu JH; Lui WY; Chang HM; Loong CC; Wu LH; Kao HL; Wu CW
Cytometry; 1997 Dec; 30(6):317-23. PubMed ID: 9440824
[TBL] [Abstract][Full Text] [Related]
8. [Expression of HLA-I antigens in primary hepatocellular carcinoma].
Huang J; Cai M; Li G; Wei D; Tan Y
Hua Xi Yi Ke Da Xue Xue Bao; 2001 Dec; 32(4):495-6, 504. PubMed ID: 12528529
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma.
Mizukoshi E; Nakamoto Y; Marukawa Y; Arai K; Yamashita T; Tsuji H; Kuzushima K; Takiguchi M; Kaneko S
Hepatology; 2006 Jun; 43(6):1284-94. PubMed ID: 16729333
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cells pulsed with gp96-peptide complexes derived from human hepatocellular carcinoma (HCC) induce specific cytotoxic T lymphocytes.
Wang XH; Qin Y; Hu MH; Xie Y
Cancer Immunol Immunother; 2005 Oct; 54(10):971-80. PubMed ID: 15965645
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of DC fused with allogeneic hepatocellular carcinoma cell line HepG2 and autologous tumor cells as potential cancer vaccines against hepatocellular carcinoma.
Cao DY; Yang JY; Yue SQ; Tao KS; Song ZS; Wang DS; Yang YL; Dou KF
Cell Immunol; 2009; 259(1):13-20. PubMed ID: 19545862
[TBL] [Abstract][Full Text] [Related]
12. Identification of a novel HLA-A2-restricted mutated Survivin epitope and induction of specific anti-HCC CTLs that could effectively cross-recognize wild-type Survivin antigen.
Shen H; Shao HW; Chen XH; Wu FL; Wang H; Huang ZL; Shen J; Wang T; Zhang WF; Huang SL
Cancer Immunol Immunother; 2013 Feb; 62(2):393-403. PubMed ID: 22926105
[TBL] [Abstract][Full Text] [Related]
13. Decreased expression of B7 costimulatory molecules and major histocompatibility complex class-I in human hepatocellular carcinoma.
Fujiwara K; Higashi T; Nouso K; Nakatsukasa H; Kobayashi Y; Uemura M; Nakamura S; Sato S; Hanafusa T; Yumoto Y; Naito I; Shiratori Y
J Gastroenterol Hepatol; 2004 Oct; 19(10):1121-7. PubMed ID: 15377288
[TBL] [Abstract][Full Text] [Related]
14. CD4+ hepatic cancer-specific cytotoxic T lymphocytes in patients with hepatocellular carcinoma.
Nakao M; Sata M; Saitsu H; Yutani S; Kawamoto M; Kojiro M; Itoh K
Cell Immunol; 1997 May; 177(2):176-81. PubMed ID: 9178645
[TBL] [Abstract][Full Text] [Related]
15. Cancer-testis Antigen OY-TES-1 Expression and Immunogenicity in Hepatocellular Carcinoma.
Luo B; Yun X; Li J; Fan R; Guo WW; Liu C; Lin YD; Ge YY; Zeng X; Bi SQ; Nong WX; Zhang QM; Xie XX
Curr Med Sci; 2020 Aug; 40(4):719-728. PubMed ID: 32862383
[TBL] [Abstract][Full Text] [Related]
16. Prediction of HLA-A2-restricted CTL epitope specific to HCC by SYFPEITHI combined with polynomial method.
Dong HL; Sui YF
World J Gastroenterol; 2005 Jan; 11(2):208-11. PubMed ID: 15633217
[TBL] [Abstract][Full Text] [Related]
17. Induction of specific cytolytic T lymphocytes using fusions of hepatocellular carcinoma (HCC) patient-derived dendritic cells and allogeneic HCC cell line.
Yin XY; Wang L; Lu MD; Li BJ; Huang JF
Hepatogastroenterology; 2008; 55(81):155-9. PubMed ID: 18507097
[TBL] [Abstract][Full Text] [Related]
18. Induction of cytotoxic T lymphocytes from the peripheral blood of a hepatocellular carcinoma patient using melanoma antigen-1 (MAGE-1) peptide.
Lu J; Leng X; Peng J; Mou D; Pang X; Shang X; Chen W
Chin Med J (Engl); 2002 Jul; 115(7):1002-5. PubMed ID: 12150730
[TBL] [Abstract][Full Text] [Related]
19. Novel natural killer cell-mediated cancer immunotherapeutic activity of anisomycin against hepatocellular carcinoma cells.
Kim M; Lee SJ; Shin S; Park KS; Park SY; Lee CH
Sci Rep; 2018 Jul; 8(1):10668. PubMed ID: 30006566
[TBL] [Abstract][Full Text] [Related]
20. [Induction of specific CD8(+) T cells against hepatocellular carcinoma-associated neoantigens].
Wang YM; Zhao BH; Chen K; Li ZJ; Qu CF
Zhonghua Zhong Liu Za Zhi; 2019 Jun; 41(6):429-434. PubMed ID: 31216828
[No Abstract] [Full Text] [Related]
[Next] [New Search]
